Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial

Abstract Background The ambitious goal to eliminate new pediatric HIV infections by 2030 requires accelerated prevention strategies in high-risk settings such as South Africa. One approach could be pre-exposure prophylaxis (PrEP) with broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs). Th...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Ameena Goga, Trisha Ramraj, Logashvari Naidoo, Brodie Daniels, Masefetsane Matlou, Terusha Chetty, Reshmi Dassaye, Nobubelo K. Ngandu, Laura Galli, Tarylee Reddy, Ishen Seocharan, Qondeni Ndlangamandla, Qholokazi September, Nokwanda Ngcobo, Mayuri Reddy, Tamon Cafun-Naidoo, Kubashni Woeber, Nitesha Jeenarain, Rabia Imamdin, Keshnee Maharajh, Ashmintha Ramjeth, Thobile Bhengu, Emma Clarence, Philippe Van de Perre, Thorkild Tylleskär, Nicolas Nagot, Jean-Pierre Moles, Penny L. Moore, Nonhlanhla N. Mkhize, Lucio Gama, Stefania Dispinseri, Priscilla Biswas, Gabriella Scarlatti, the PedMAb1 clinical trial team
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2024-07-01
Ráidu:	BMC Infectious Diseases
Fáttát:	HIV Broadly neutralizing antibody Vertical transmission of HIV-1 Vertical transmission Breastfeeding Pre-exposure prophylaxis
Liŋkkat:	https://doi.org/10.1186/s12879-024-09588-3
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!